Targeted treatment in mast cell tumors
Masivet® (masitinib) is a tyrosine kinase inhibitor that selectively targets c-Kit. The drug is used in non-metastatic, inoperable mast cell tumors and may be employed as part of a broader treatment strategy in dogs.
What is Masivet?
Masivet is designed for dogs with grade 2 or 3 mast cell tumors without metastases that cannot be surgically removed. It selectively inhibits the action of certain enzymes (such as KIT) involved in tumor growth.
In doing so, Masivet supports the management of tumors at the molecular level - targeted, but tailored to the individual patient.
For whom, why, when, how?
For whom.
For dogs with inoperable, non-metastatic mast cell tumors. Preferably with (suspected) c-Kit mutation
Why?
As part of a careful treatment plan. Used when surgery is not an option, or as additional support in consultation with the veterinarian.
When?
Always on veterinary prescription. Masivet is a prescription veterinary drug and is dispensed exclusively through the practice.
How?
Once daily by oral administration. Administration in tablet form according to body weight. Under the supervision of a veterinarian.
